Effect of metoprolol in acute coxsackievirus B3 murine myocarditis
S Rezkalla,
RA Kloner,
G Khatib,
FE Smith,
and
R Khatib
Department of Medicine, Wayne State University, Detroit, Michigan.
Recent studies suggest that beta-adrenergic blocking agents show promise in the management of cardiomyopathies; however, their role in acute myocarditis is unknown. One hundred 3 week old mice were infected with coxsackievirus B3 and were given either metoprolol (n = 50) or normal saline solution (n = 50) intraperitoneally for 10 days. Twenty mice from each group were observed for mortality for 30 days. Of the remaining 60 mice, 10 from each group were killed on day 3, 6 or 10 and examined for heart viral titers and pathologic changes. Mortality rate in the metoprolol group was 60% compared with 0% in the saline group (p less than 0.005). Viral titers on day 10 of infection were 10(2.6 +/- 0.2) median tissue culture infective dose for the metoprolol group versus 10(2.1 +/- 0.1) for the saline group (p less than 0.05). Whereas pathologic changes at days 3, 6 and 10 of infection were similar in both groups, on day 30 of infection, inflammation, necrosis and mineralization scores (mean +/- SEM) were 1.1 +/- 0.3, 2.1 +/- 0.4, 2.2 +/- 0.5 for the metoprolol group versus 0.3 +/- 0.1, 0.4 +/- 0.3, 0.4 +/- 0.3 for the saline group, respectively (p less than 0.01). Six noninfected mice received metoprolol intraperitoneally for 10 days; there was no mortality during 30 days of observation. In conclusion, metoprolol administration exerts deleterious effects in acute coxsackievirus B3 murine myocarditis.
This article has been cited by other articles:
|
|
|
|
 
J.-F. Wang, A. Meissner, S. Malek, Y. Chen, Q. Ke, J. Zhang, V. Chu, T. G. Hampton, C. S. Crumpacker, W. H. Abelmann, et al.
Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis
Am J Physiol Heart Circ Physiol,
October 1, 2005;
289(4):
H1577 - H1583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yuan, K. Shioji, Y. Kihara, H. Takenaka, Y. Onozawa, and C. Kishimoto
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property
Am J Physiol Heart Circ Physiol,
January 1, 2004;
286(1):
H83 - H90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Leon, K. Wang, and D. M. Engman
Captopril Ameliorates Myocarditis in Acute Experimental Chagas Disease
Circulation,
May 6, 2003;
107(17):
2264 - 2269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takada, C. Kishimoto, and Y. Hiraoka
Therapy With Immunoglobulin Suppresses Myocarditis in a Murine Coxsackievirus B3 Model : Antiviral and Anti-inflammatory Effects
Circulation,
September 15, 1995;
92(6):
1604 - 1611.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
J.-F. Wang, J. Zhang, J.-Y. Min, M. F. Sullivan, C. S. Crumpacker, W. H. Abelmann, and J. P. Morgan
Cocaine enhances myocarditis induced by encephalomyocarditis virus in murine model
Am J Physiol Heart Circ Physiol,
March 1, 2002;
282(3):
H956 - H963.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
